|
|
OX-40 / CD134 (BSB-90), MMab
SKU: |
BSB 3120 (ASR) |
Antibody type:
|
Mouse Monoclonal
|
Clone:
|
BSB-90
|
Isotype:
|
IgG1
|
Concentrate Dilution:
|
1:25-1:100
|
Localization:
|
Cytoplasmic, Membranous
|
Tissue Control:
|
Tonsil, Lymph Node, Thymus
|
Species Reactivity:
|
Human
|
|
Intended Use
Analyte Specific Reagent
Summary and Explanation
OX-40 also known as CD134 and Tumor Necrosis Factor Receptor Superfamily Member 4 (TNFRSF4), is a member of the TNFR-superfamily of receptors which is not constitutively expressed on activated CD4 and CD8 T cells as well as a number of other lymphoid and non-lymphoid cells, unlike CD28. OX-40 and its binding partner, OX40L (CD252), are costimulatory signals from OX-40 to a conventional T cell to promote division and survival, augmenting the clonal expansion of effector and memory populations as they are being generated to antigen. OX-40 and OX-40L also regulate cytokine production from T cells, antigen-presenting cells, NK cells, and NKT cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX-40/OX-40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases. Besides the essential role played by OX-40 signaling in generating memory CD4 T cells, recent reports show that it also has a unique role in generating memory CD8 T cells. In addition, recent genome-wide association studies have identified single-nucleotide polymorphisms of the OX-40L and OX-40 genes that are related to cardiovascular diseases and SLE, providing direct evidence for the involvement of the OX-40/OX-40L interaction in human diseases.
OX-40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX-40 antibody engagement by ligands present on dendritic cells dramatically increases the proliferation, effector function, and survival of T cells. Preclinical studies have shown that OX-40 agonists increase anti-tumor immunity and improve tumor-free survival by increasing T and B cell responses to reporter antigen immunizations, led to preferential up-regulation of OX-40 on CD4(+) FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, and increased the anti-tumor reactivity of T and B cells in patients with melanoma.
Presentation
OX-40 antibody (CD134 antibody) is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Synonyms: ACT35, ACT35 antigen, ATC35 antigen, CD134, CD134 antigen, lymphoid activation antigene ACT35, OX40, OX40 antigen, OX40 cell surface antigen, OX40 homologue, OX40L receptor, TAX transcriptionally activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TXGP1L, anti-ox-40, anti-ox40, anti ox-40, anti ox40, anti-cd134, anti cd134
Specification Sheets
Safety Data Sheets
There are currently no questions about this
product.
Ask a Question
Option | SKU | Price |
Presentation: 3 ml Predilute | BSB 3120 (ASR) | $137.00 |
Presentation: 7 ml Predilute | BSB 3121 (ASR) | $341.00 |
Presentation: 15 ml Predilute | BSB 3122 (ASR) | $681.00 |
Presentation: .1 ml Concentrate | BSB 3123 (ASR) | $114.00 |
Presentation: .5 ml Concentrate | BSB 3124 (ASR) | $341.00 |
Presentation: 1 ml Concentrate | BSB 3125 (ASR) | $624.00 |
Presentation: Control Slides [5] | BSB 3126 | $63.00 |
|
|
|